GGrantIndex
Sort

48,018 grants matching immunotherapy

Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP

$1,122,303
Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Surgery Branch Cell Prep Core

$1,122,261
John Wunderlich · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA

Cell Production Core Facility

$1,122,261
John Wunderlich · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA

Examining IL-15 and IL-7 as an immunotherapy agent in cancer and AIDS

$1,121,375
Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Control of Cytokine Gene Expression in LymphoidMyeloid Cells

$1,119,930
Howard A Young · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

Microparticle Therapy for Cerebral Amyloid Angiopathy

$1,119,539
Wolff M. Kirsch · Karamedica, Inc. · R44 · FY2021 · AG

Philadelphia Pediatric AIDS Clinical Trials Unit

$1,119,014
Children'S Hospital Of Philadelphia · U01 · FY2002 · AI

Ann Arbor regional CCOP

$1,118,919
Saint Joseph Mercy Health System · U10 · FY2004 · CA

Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea

$1,118,405
Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2019 · AI

Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma

$1,117,983
Isabel Kurth · Rgenix, Inc. · R44 · FY2016 · CA

Innovations in Functional B Cell Epitope Discovery for Food Allergy

$1,117,972
Scott Boyd · Stanford University · N01 · FY2025 · AI

Immunobiology and immunotherapy of leukemia

$1,117,867
Austin J Barrett · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL

Characterization and improvement of graft versus leukemia effects

$1,117,867
Austin J Barrett · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL

Broad Spectrum Neutralizing Human Abs to SARS and Related Coronaviruses

$1,117,743
Wayne A. Marasco · Dana-Farber Cancer Inst · R01 · FY2011 · AI

A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform

$1,117,537
Shawn Hingtgen · Univ Of North Carolina Chapel Hill · U01 · FY2024 · TR

Immune Function and the Progression to Type 1 Diabetes

$1,117,395
Mark A Atkinson · University Of Florida · P01 · FY2011 · AI

Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever

$1,117,358
Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2020 · AI

Tumor Plasticity

$1,117,200
Dario C. Altieri · Wistar Institute · R35 · FY2023 · CA

Tumor Plasticity

$1,117,200
Dario C. Altieri · Wistar Institute · R35 · FY2022 · CA

Understanding the Role of the Host Response in HIVSIV Infection

$1,116,963
Genoveffa Franchini · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma

$1,116,963
Douglas F Nixon · Feinstein Institute For Medical Research · R01 · FY2024 · CA

Pediatric AIDS Clinical Trials Group

$1,116,567
St. Jude Children'S Research Hospital · U01 · FY2003 · AI

Biomarkers and Therapeutic Targets in Tumor Microenvironment and Metastasis

$1,116,420
Rosandra Kaplan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Adenosine Receptor Agonists as an Immunotherapy for Biodefense

$1,115,978
Ian Justin Glomski · University Of Virginia · U01 · FY2010 · AI

Point-of-Care Microfluidics in Lung Cancer

$1,115,405
Mehmet Toner · Massachusetts General Hospital · R01 · FY2008 · EB